This project presents a strategic healthcare market analysis of Heart Failure with Reduced Ejection Fraction (HFrEF) in the United States, focusing on market size, diagnosis rates, therapy adoption, and value concentration across treatment classes.

ðŸ”¥ðŸ”¥HFrEF in the US is a large, highly diagnosed and economically mature market.

With 3M diagnosed patients, incremental growth is no longer driven by awareness or access, but by portfolio strategy and execution excellence.

Key takeaways:

1. Value concentration today sits with ARNI, supported by strong outcomes and payer alignment

2. SGLT2 inhibitors represent the next scalable value pool, with cross-indication leverage

3. Future outperformance will be determined by differentiation, payer economics, and field execution

In saturated chronic markets, winners are defined by strategic capital allocation - not product launches alone. 

The analysis highlights how value creation in the US HFrEF market is driven by therapy differentiation, payer economics, and execution excellence, with ARNI therapies currently leading value share and SGLT2 inhibitors emerging as the next growth engine. It evaluates patient population dynamics, therapy-wise penetration, revenue distribution, and cost economics to identify priority investment areas.

From a Business Analyst and healthcare strategy perspective, the project demonstrates market segmentation, treatment class comparison, revenue analysis, and strategic insight generation to support portfolio prioritization and growth planning.

Key Insight: Sustained growth in HFrEF requires reinforcing ARNI leadership while systematically scaling SGLT2 adoption.

ðŸ”§ Tools & Skills Demonstrated

Healthcare Market Analysis â€¢ Business Strategy â€¢ Data Interpretation â€¢ Competitive & Therapy-Class Analysis â€¢ Executive-Level Insights
